ENSG00000141367 |
CLTC |
inflammatory myofibroblastic tumor |
gene_fusion |
50.0% (17/34) |
3 entries |
ENSG00000141367 |
CLTC |
breast ductal adenocarcinoma |
missense_variant |
7.192% (42/584) |
2 entries |
ENSG00000141367 |
CLTC |
lung adenocarcinoma |
sequence_alteration |
5.076% (67/1320) |
4 entries |
ENSG00000141367 |
CLTC |
anaplastic large cell lymphoma |
gene_fusion |
49.11% (55/112) |
5 entries |
ENSG00000141367 |
CLTC |
lung adenocarcinoma |
missense_variant |
5.076% (67/1320) |
5 entries |
ENSG00000141367 |
CLTC |
breast ductal adenocarcinoma |
sequence_alteration |
7.192% (42/584) |
1 entry |
ENSG00000141367 |
CLTC |
lung adenocarcinoma |
gene_fusion |
5.076% (67/1320) |
1 entry |
ENSG00000141367 |
CLTC |
colorectal adenocarcinoma |
sequence_alteration |
6.678% (76/1138) |
3 entries |
ENSG00000141367 |
CLTC |
colorectal adenocarcinoma |
missense_variant |
6.678% (76/1138) |
3 entries |
ENSG00000141367 |
CLTC |
prostate adenocarcinoma |
sequence_alteration |
2.407% (35/1454) |
3 entries |
ENSG00000141367 |
CLTC |
B-cell neoplasm |
gene_fusion |
20.0% (3/15) |
1 entry |
ENSG00000141367 |
CLTC |
skin carcinoma |
sequence_alteration |
3.846% (4/104) |
1 entry |
ENSG00000141367 |
CLTC |
Breast Carcinoma by Gene Expression Profile |
missense_variant |
15.79% (3/19) |
2 entries |
ENSG00000141367 |
CLTC |
osteosarcoma |
sequence_alteration |
1.724% (2/116) |
2 entries |
ENSG00000141367 |
CLTC |
Gastric Diffuse Large B-Cell Lymphoma |
gene_fusion |
50.0% (2/4) |
2 entries |
ENSG00000141367 |
CLTC |
diffuse large B-cell lymphoma |
sequence_alteration |
4.545% (15/330) |
1 entry |
ENSG00000141367 |
CLTC |
gastric adenocarcinoma |
missense_variant |
2.33% (13/558) |
1 entry |
ENSG00000141367 |
CLTC |
clear cell renal carcinoma |
missense_variant |
0.8708% (12/1378) |
1 entry |
ENSG00000141367 |
CLTC |
chronic lymphocytic leukemia |
sequence_alteration |
1.014% (9/888) |
1 entry |
ENSG00000141367 |
CLTC |
small cell lung carcinoma |
missense_variant |
1.238% (4/323) |
2 entries |
ENSG00000141367 |
CLTC |
esophageal squamous cell carcinoma |
missense_variant |
1.627% (11/676) |
5 entries |
ENSG00000141367 |
CLTC |
esophageal adenocarcinoma |
sequence_alteration |
4.795% (21/438) |
1 entry |
ENSG00000141367 |
CLTC |
bladder transitional cell carcinoma |
sequence_alteration |
4.639% (9/194) |
3 entries |
ENSG00000141367 |
CLTC |
squamous cell lung carcinoma |
sequence_alteration |
3.815% (33/865) |
2 entries |
ENSG00000141367 |
CLTC |
papillary renal cell carcinoma |
sequence_alteration |
1.69% (6/355) |
1 entry |
ENSG00000141367 |
CLTC |
skin melanoma |
sequence_alteration |
1.861% (18/967) |
3 entries |
ENSG00000141367 |
CLTC |
colon adenocarcinoma |
missense_variant |
4.848% (35/722) |
4 entries |
ENSG00000141367 |
CLTC |
esophageal adenocarcinoma |
missense_variant |
4.795% (21/438) |
1 entry |
ENSG00000141367 |
CLTC |
melanoma |
missense_variant |
1.98% (2/101) |
2 entries |
ENSG00000141367 |
CLTC |
hemangioblastoma |
sequence_alteration |
6.25% (2/32) |
1 entry |
ENSG00000141367 |
CLTC |
skin melanoma |
missense_variant |
1.861% (18/967) |
3 entries |
ENSG00000141367 |
CLTC |
hepatocellular carcinoma |
missense_variant |
1.996% (18/902) |
2 entries |
ENSG00000141367 |
CLTC |
renal carcinoma |
gene_fusion |
18.18% (2/11) |
2 entries |
ENSG00000141367 |
CLTC |
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
1 entry |
ENSG00000141367 |
CLTC |
brain glioblastoma |
sequence_alteration |
0.9719% (9/926) |
2 entries |
ENSG00000141367 |
CLTC |
gastric intestinal type adenocarcinoma |
sequence_alteration |
3.529% (3/85) |
1 entry |
ENSG00000141367 |
CLTC |
esophageal squamous cell carcinoma |
sequence_alteration |
1.627% (11/676) |
3 entries |
ENSG00000141367 |
CLTC |
melanoma |
sequence_alteration |
1.98% (2/101) |
2 entries |
ENSG00000141367 |
CLTC |
basal cell carcinoma |
sequence_alteration |
8.621% (5/58) |
1 entry |
ENSG00000141367 |
CLTC |
bladder transitional cell carcinoma |
missense_variant |
4.639% (9/194) |
2 entries |
ENSG00000141367 |
CLTC |
neoplasm of mature B-cells |
sequence_alteration |
5.882% (2/34) |
2 entries |
ENSG00000141367 |
CLTC |
adenosquamous lung carcinoma |
gene_fusion |
17.65% (3/17) |
1 entry |
ENSG00000141367 |
CLTC |
squamous cell lung carcinoma |
gene_fusion |
3.815% (33/865) |
1 entry |
ENSG00000141367 |
CLTC |
ovarian serous adenocarcinoma |
missense_variant |
0.2972% (2/673) |
1 entry |
ENSG00000141367 |
CLTC |
diffuse large B-cell lymphoma |
gene_fusion |
4.545% (15/330) |
6 entries |
ENSG00000141367 |
CLTC |
rectal adenocarcinoma |
missense_variant |
1.81% (4/221) |
1 entry |
ENSG00000141367 |
CLTC |
colon adenocarcinoma |
frameshift_variant |
4.848% (35/722) |
2 entries |
ENSG00000141367 |
CLTC |
large cell lung carcinoma |
gene_fusion |
19.23% (5/26) |
1 entry |
ENSG00000141367 |
CLTC |
Ampulla of Vater Carcinoma |
missense_variant |
1.015% (2/197) |
1 entry |
ENSG00000141367 |
CLTC |
prostate carcinoma |
missense_variant |
3.093% (15/485) |
2 entries |
ENSG00000141367 |
CLTC |
basal cell carcinoma |
missense_variant |
8.621% (5/58) |
1 entry |
ENSG00000141367 |
CLTC |
small cell lung carcinoma |
sequence_alteration |
1.238% (4/323) |
2 entries |
ENSG00000141367 |
CLTC |
prostate carcinoma |
sequence_alteration |
3.093% (15/485) |
2 entries |
ENSG00000141367 |
CLTC |
papillary renal cell carcinoma |
missense_variant |
1.69% (6/355) |
1 entry |
ENSG00000141367 |
CLTC |
prostate adenocarcinoma |
missense_variant |
2.407% (35/1454) |
2 entries |
ENSG00000141367 |
CLTC |
hepatocellular carcinoma |
sequence_alteration |
1.996% (18/902) |
2 entries |
ENSG00000141367 |
CLTC |
colorectal adenocarcinoma |
conservative_inframe_deletion |
6.678% (76/1138) |
1 entry |
ENSG00000141367 |
CLTC |
clear cell renal carcinoma |
sequence_alteration |
0.8708% (12/1378) |
2 entries |
ENSG00000141367 |
CLTC |
Bladder Inflammatory Myofibroblastic Tumor |
gene_fusion |
50.0% (2/4) |
2 entries |
ENSG00000141367 |
CLTC |
cecum adenocarcinoma |
sequence_alteration |
5.6% (7/125) |
1 entry |
ENSG00000141367 |
CLTC |
HER2 Positive Breast Carcinoma |
missense_variant |
8.861% (14/158) |
2 entries |
ENSG00000141367 |
CLTC |
female breast carcinoma |
sequence_alteration |
1.535% (6/391) |
1 entry |
ENSG00000141367 |
CLTC |
squamous cell lung carcinoma |
missense_variant |
3.815% (33/865) |
2 entries |
ENSG00000141367 |
CLTC |
colon adenocarcinoma |
sequence_alteration |
4.848% (35/722) |
7 entries |
ENSG00000141367 |
CLTC |
dedifferentiated chondrosarcoma |
sequence_alteration |
15.38% (2/13) |
1 entry |
ENSG00000141367 |
CLTC |
HER2 Positive Breast Carcinoma |
sequence_alteration |
8.861% (14/158) |
2 entries |
ENSG00000141367 |
CLTC |
bladder transitional cell carcinoma |
frameshift_variant |
4.639% (9/194) |
2 entries |
ENSG00000141367 |
CLTC |
neoplasm of mature B-cells |
missense_variant |
5.882% (2/34) |
2 entries |
ENSG00000141367 |
CLTC |
cecum adenocarcinoma |
stop_gained |
5.6% (7/125) |
1 entry |
ENSG00000141367 |
CLTC |
cecum adenocarcinoma |
missense_variant |
5.6% (7/125) |
2 entries |
ENSG00000141367 |
CLTC |
Ampulla of Vater Carcinoma |
sequence_alteration |
1.015% (2/197) |
1 entry |
ENSG00000141367 |
CLTC |
alveolar rhabdomyosarcoma |
missense_variant |
1.695% (1/59) |
1 entry |
ENSG00000141367 |
CLTC |
head and neck squamous cell carcinoma |
missense_variant |
0.1597% (1/626) |
1 entry |
ENSG00000141367 |
CLTC |
large cell lung carcinoma |
sequence_alteration |
19.23% (5/26) |
1 entry |
ENSG00000141367 |
CLTC |
skin carcinoma |
missense_variant |
3.846% (4/104) |
1 entry |
ENSG00000141367 |
CLTC |
Renal Cell Carcinoma Associated with Xp11.2 Translocations/TFE3 Gene Fusions |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
B-cell non-Hodgkins lymphoma |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
prostate carcinoma |
stop_gained |
3.093% (15/485) |
1 entry |
ENSG00000141367 |
CLTC |
ovarian carcinoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000141367 |
CLTC |
renal cell carcinoma |
sequence_alteration |
9.091% (1/11) |
1 entry |
ENSG00000141367 |
CLTC |
Parathyroid Gland Carcinoma |
sequence_alteration |
5.263% (1/19) |
1 entry |
ENSG00000141367 |
CLTC |
polycythemia vera |
sequence_alteration |
2.083% (1/48) |
1 entry |
ENSG00000141367 |
CLTC |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.3367% (2/594) |
1 entry |
ENSG00000141367 |
CLTC |
medullary thyroid gland carcinoma |
sequence_alteration |
5.263% (1/19) |
1 entry |
ENSG00000141367 |
CLTC |
chromophobe renal cell carcinoma |
frameshift_variant |
0.8696% (1/115) |
1 entry |
ENSG00000141367 |
CLTC |
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000141367 |
CLTC |
Merkel cell skin cancer |
sequence_alteration |
3.333% (1/30) |
1 entry |
ENSG00000141367 |
CLTC |
large cell lung carcinoma |
missense_variant |
19.23% (5/26) |
1 entry |
ENSG00000141367 |
CLTC |
diffuse large B-cell lymphoma |
missense_variant |
4.545% (15/330) |
1 entry |
ENSG00000141367 |
CLTC |
chondroblastoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000141367 |
CLTC |
bladder transitional cell carcinoma |
stop_gained |
4.639% (9/194) |
1 entry |
ENSG00000141367 |
CLTC |
angiosarcoma |
sequence_alteration |
7.692% (1/13) |
1 entry |
ENSG00000141367 |
CLTC |
diffuse gastric adenocarcinoma |
sequence_alteration |
1.266% (1/79) |
1 entry |
ENSG00000141367 |
CLTC |
small intestinal adenocarcinoma |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000141367 |
CLTC |
medullary thyroid gland carcinoma |
stop_gained |
5.263% (1/19) |
1 entry |
ENSG00000141367 |
CLTC |
metaplastic breast carcinoma |
missense_variant |
1.961% (1/51) |
1 entry |
ENSG00000141367 |
CLTC |
osteosarcoma |
missense_variant |
1.724% (2/116) |
1 entry |
ENSG00000141367 |
CLTC |
chronic myelomonocytic leukemia |
missense_variant |
1.053% (1/95) |
1 entry |
ENSG00000141367 |
CLTC |
dedifferentiated chondrosarcoma |
missense_variant |
15.38% (2/13) |
1 entry |
ENSG00000141367 |
CLTC |
Lung Inflammatory Myofibroblastic Tumor |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
T-cell acute lymphoblastic leukemia |
stop_gained |
0.3367% (2/594) |
1 entry |
ENSG00000141367 |
CLTC |
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
0.5988% (1/167) |
1 entry |
ENSG00000141367 |
CLTC |
renal cell carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000141367 |
CLTC |
bile duct adenocarcinoma |
sequence_alteration |
0.5291% (1/189) |
1 entry |
ENSG00000141367 |
CLTC |
pulmonary mucoepidermoid carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
basal cell carcinoma |
stop_gained |
8.621% (5/58) |
1 entry |
ENSG00000141367 |
CLTC |
chromophobe renal cell carcinoma |
sequence_alteration |
0.8696% (1/115) |
1 entry |
ENSG00000141367 |
CLTC |
female breast carcinoma |
missense_variant |
1.535% (6/391) |
1 entry |
ENSG00000141367 |
CLTC |
Parathyroid Gland Carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000141367 |
CLTC |
chronic myelomonocytic leukemia |
sequence_alteration |
1.053% (1/95) |
1 entry |
ENSG00000141367 |
CLTC |
T-cell acute lymphoblastic leukemia |
sequence_alteration |
0.3367% (2/594) |
1 entry |
ENSG00000141367 |
CLTC |
Liver Inflammatory Myofibroblastic Tumor |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
female breast carcinoma |
stop_gained |
1.535% (6/391) |
1 entry |
ENSG00000141367 |
CLTC |
Small Intestinal Diffuse Large B-Cell Lymphoma |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000141367 |
CLTC |
osteosarcoma |
frameshift_variant |
1.724% (2/116) |
1 entry |